Dr. Hasleton serves as Oramed’s Vice President of Business Development.
Mark has over 15 years Pharma / Biotech experience including Medical, Marketing, R&D and Business Development.
Prior to joining the Oramed, Mark served in several leadership and pharmaceutical development roles. From 2010 to 2018, he served in Business Development and later as Senior Director of Portfolio – Global New Therapeutic Entities at Teva Pharmaceutical Industries Ltd. Prior to joining Teva, from 2007 to 2010, Mark was at Bristol Myers Squibb Co, in the UK and then in the European business as EMEA Business Operations Manager for MSLs in the region.
Mark has a PhD in molecular biology and cancer research from the Imperial College London, UK, a MRes in molecular biology from the University of Manchester, UK and an MBA from Tanaka Business School, Imperial College London, UK.